Clinical Trial Update: Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and safety/tolerability study of a single subcutaneous PB1023 dose conducted in subjects with normal and impaired renal function, in the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PB1023

Snippet

Sponsor: PhaseBio Pharmaceuticals Inc. | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED